tetano
Editor, Senior Moderator
Sci Rep
. 2022 Apr 9;12(1):5999.
doi: 10.1038/s41598-022-10057-7.
The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech)
Jessica Andries[SUP] #[/SUP][SUP] 1 [/SUP], Wildriss Viranaicken[SUP] #[/SUP][SUP] 1 [/SUP], Colette Cordonin[SUP] 2 [/SUP], Charline Herrscher[SUP] 1 [/SUP], Cynthia Planesse[SUP] 3 [/SUP], Bénédicte Roquebert[SUP] 4 [/SUP], Marie Lagrange-Xelot[SUP] 5 [/SUP], Chaker El-Kalamouni[SUP] 1 [/SUP], Olivier Meilhac[SUP] 3 [/SUP], Patrick Mavingui[SUP] 1 [/SUP], David Couret[SUP] 3 6 [/SUP], Gilles Gadea[SUP] 1 7 [/SUP], Philippe Despres[SUP] 8 [/SUP]
Affiliations
Abstract
The newly identified coronavirus SARS-CoV-2 is responsible for the worldwide pandemic COVID-19. Considerable efforts have been devoted for the development of effective vaccine strategies against COVID-19. The SARS-CoV-2 spike protein has been identified as the major antigen candidate for the development of COVID-19 vaccines. The Pfizer-BioNTech COVID-19 vaccine COMIRNATY is a lipid nanoparticle-encapsulated mRNA encoding a full-length and prefusion-stabilized SARS-CoV-2 spike protein. In the present study, synthetic peptide-based ELISA assays were performed to identify linear B-cell epitopes into the spike protein that contribute to elicitation of antibody response in COMIRNATY-vaccinated individuals. The synthetic S2P6 peptide containing the spike residues 1138/1169 and to a lesser extent, the synthetic S1P4 peptide containing the spike residues 616/644 were recognized by the immune sera from COMIRNATY vaccine recipients but not COVID-19 recovered patients. We assume that the synthetic S2P6 peptide and to a lesser extent the synthetic S1P4 peptide, could be of interest to measure the dynamic of antibody response to COVID-19 mRNA vaccines. The S2P6 peptide has been identified as immunogenic in adult BALB/c mice that received protein-peptide conjugates in a prime-boost schedule. This raises the question on the role of the B-cell epitope peptide containing the SARS-CoV-2 spike residues 1138/1169 in protective efficacy of the Pfizer-BioNTech COVID-19 vaccine COMIRNATY.
. 2022 Apr 9;12(1):5999.
doi: 10.1038/s41598-022-10057-7.
The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech)
Jessica Andries[SUP] #[/SUP][SUP] 1 [/SUP], Wildriss Viranaicken[SUP] #[/SUP][SUP] 1 [/SUP], Colette Cordonin[SUP] 2 [/SUP], Charline Herrscher[SUP] 1 [/SUP], Cynthia Planesse[SUP] 3 [/SUP], Bénédicte Roquebert[SUP] 4 [/SUP], Marie Lagrange-Xelot[SUP] 5 [/SUP], Chaker El-Kalamouni[SUP] 1 [/SUP], Olivier Meilhac[SUP] 3 [/SUP], Patrick Mavingui[SUP] 1 [/SUP], David Couret[SUP] 3 6 [/SUP], Gilles Gadea[SUP] 1 7 [/SUP], Philippe Despres[SUP] 8 [/SUP]
Affiliations
- PMID: 35397679
- DOI: 10.1038/s41598-022-10057-7
Abstract
The newly identified coronavirus SARS-CoV-2 is responsible for the worldwide pandemic COVID-19. Considerable efforts have been devoted for the development of effective vaccine strategies against COVID-19. The SARS-CoV-2 spike protein has been identified as the major antigen candidate for the development of COVID-19 vaccines. The Pfizer-BioNTech COVID-19 vaccine COMIRNATY is a lipid nanoparticle-encapsulated mRNA encoding a full-length and prefusion-stabilized SARS-CoV-2 spike protein. In the present study, synthetic peptide-based ELISA assays were performed to identify linear B-cell epitopes into the spike protein that contribute to elicitation of antibody response in COMIRNATY-vaccinated individuals. The synthetic S2P6 peptide containing the spike residues 1138/1169 and to a lesser extent, the synthetic S1P4 peptide containing the spike residues 616/644 were recognized by the immune sera from COMIRNATY vaccine recipients but not COVID-19 recovered patients. We assume that the synthetic S2P6 peptide and to a lesser extent the synthetic S1P4 peptide, could be of interest to measure the dynamic of antibody response to COVID-19 mRNA vaccines. The S2P6 peptide has been identified as immunogenic in adult BALB/c mice that received protein-peptide conjugates in a prime-boost schedule. This raises the question on the role of the B-cell epitope peptide containing the SARS-CoV-2 spike residues 1138/1169 in protective efficacy of the Pfizer-BioNTech COVID-19 vaccine COMIRNATY.